For instance, Barragan [27] and Tian [28] indicated that NQO1 polymorphism rs1800566 has predictive usefulness toward clinical response to induction therapy (anthracycline- and cytarabine-based regimen) in acute myeloid leukemia (AML) and platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients, respectively. The gene discussed is NQO1; the disease is acute myeloid leukemia.